Therapure Biopharma Inc. signs fill/finish contract with OPK Biotech LLC.
Mississauga, Ontario, Canada (July 15, 2010 )Therapure Biopharma Inc.(Therapure) today announced the signing of an agreement under which it will provide fill/finish services for OPK Biotech LLC (OPK), a biotechnology company based in Cambridge, Massachusetts . Under the terms of the agreement, Therapure will provide fill/finish services to support development for one of OPK’s therapeutic products, which is used to increase oxygen transport. The companies are also negotiating a contract for on-going GMP manufacturing services. Financial terms were not disclosed.
OPK is a Massachusetts based company that develops and brings to market innovative drugs in the class of oxygen therapeutics. Using proprietary technology, two products have been developed and manufactured: Hemopure® (HBOC-201) [hemoglobin glutamer - 250 (bovine)] for human use and Oxyglobin® (HBOC-301) [hemoglobin glutamer - 200 (bovine)] for veterinary use.
“We are proud to have been chosen by OPK as its partner to provide fill/finish services” said Thomas Wellner, President and CEO of Therapure. “Not only does Therapure have a deep understanding of the HBOC market, it also has demonstrated market leading expertise with fill/finish services,” continued Mr. Wellner.
“OPK was seeking a service provider with scientific expertise in oxygen therapeutics,” said Zafiris Zafirelis, COO of OPK. “This project is important to OPK’s product line and we are confident in Therapure’s ability to meet our needs”.
Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies and packages therapeutic proteins. As a contract development and manufacturing organization (CDMO) Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop effective and innovative solutions to advance products from discovery to market for its clients. Therapure’s Health Canada licensed 130,000 sq. ft. facility, includes manufacturing, research and quality control laboratories and a cGMP warehouse, and is built to U.S. FDA, EMEA, MHRA and Health Canada standards for the aseptic handling and purification of proteins.
For more information, please visit: www.therapurebio.com
Thomas Wellner, President and CEO
Therapure Biopharma Inc.
+1 905 286-620